Approaching the final week of November CSL Ltd ADR (OTCMKTS: CSLLY) received some good news as the United States Food and Drug Administration approved CSL Behring’s new gene therapy drug, HEMEGENIX ...
CSL shares slump to levels last seen in December 2017. The post Why the CSL share price just hit a 9-year low appeared first ...
With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...
CSL Limited has left its current fiscal year financial guidance unchanged, which I deem to be too conservative. There are various indicators suggesting that the company's actual topline expansion and ...
Stockhead on MSN
Dr Boreham’s Crucible: CSL’s tough diagnosis
A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...
I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and ...
Australian biotech giant CSL Ltd CSL.AX' reported on Tuesday a net profit rise of 13% in the first half, bolstered by strong demand and increased plasma collection at its Behring unit. The company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results